Swiss National Bank
AKBA icon

Swiss National Bank’s Akebia Therapeutics AKBA Stock Holding History

Swiss National Bank’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-496,700
Closed -$800K – 2302
2025
Q4 		$800K Sell
496,700
-12,600
-2% -$26.4K ﹤0.01% 2236
2025
Q3 		$1.39M Buy
+509,300
New +$1.69M ﹤0.01% 2017
2022
Q2 		– Sell
-393,085
Closed -$282K – 2741
2022
Q1 		$282K Buy
393,085
+28,300
+8% +$60.5K ﹤0.01% 2663
2021
Q4 		$824K Buy
364,785
+28,700
+9% +$78.3K ﹤0.01% 2545
2021
Q3 		$968K Buy
336,085
+14,600
+5% +$41.7K ﹤0.01% 2451
2021
Q2 		$1.22M Buy
321,485
+7,700
+2% +$25.9K ﹤0.01% 2388
2021
Q1 		$1.06M Buy
313,785
+9,700
+3% +$34.9K ﹤0.01% 2325
2020
Q4 		$851K Hold
304,085
– – ﹤0.01% 2358
2020
Q3 		$763K Buy
304,085
+51,800
+21% +$455K ﹤0.01% 2231
2020
Q2 		$3.43M Buy
252,285
+102,300
+68% +$1.06M ﹤0.01% 1378
2020
Q1 		$1.14M Buy
149,985
+2,100
+1% +$16.3K ﹤0.01% 1753
2019
Q4 		$935K Buy
147,885
+4,100
+3% +$19.5K ﹤0.01% 2174
2019
Q3 		$564K Buy
143,785
+5,200
+4% +$22.3K ﹤0.01% 2321
2019
Q2 		$671K Hold
138,585
– – ﹤0.01% 2315
2019
Q1 		$1.14M Sell
138,585
-5,900
-4% -$40.5K ﹤0.01% 1997
2018
Q4 		$799K Buy
144,485
+66,385
+85% +$520K ﹤0.01% 2129
2018
Q3 		$690K Hold
78,100
– – ﹤0.01% 2321
2018
Q2 		$779K Hold
78,100
– – ﹤0.01% 2303
2018
Q1 		$744K Buy
78,100
+13,800
+21% +$193K ﹤0.01% 2247
2017
Q4 		$956K Buy
+64,300
New +$1.07M ﹤0.01% 2118
2015
Q2 		– Sell
-17,200
Closed -$191K – 2582
2015
Q1 		$191K Hold
17,200
– – ﹤0.01% 2489
2014
Q4 		$200K Buy
+17,200
New +$247K ﹤0.01% 2505

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Swiss National Bank's AKBA Position: Q1 2026 in Review

Swiss National Bank sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 496,700 shares — an estimated $800K sold.

Swiss National Bank first reported a position in AKBA in Q4 2014 and held it in 22 quarters. The position peaked at $3.43M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Swiss National Bank reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Swiss National Bank sold 496,700 Akebia Therapeutics shares in Q1 2026, an estimated $800K.
  • Swiss National Bank first reported a position in Akebia Therapeutics in Q4 2014 and held it in 22 quarters.
  • Swiss National Bank's Akebia Therapeutics position peaked at $3.43M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.